CN112689507B - 具有无支链接头的氨基酸化合物及其使用方法 - Google Patents

具有无支链接头的氨基酸化合物及其使用方法 Download PDF

Info

Publication number
CN112689507B
CN112689507B CN201980050125.6A CN201980050125A CN112689507B CN 112689507 B CN112689507 B CN 112689507B CN 201980050125 A CN201980050125 A CN 201980050125A CN 112689507 B CN112689507 B CN 112689507B
Authority
CN
China
Prior art keywords
tetrahydro
naphthyridin
compound
nonanoic acid
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980050125.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN112689507A (zh
Inventor
K·莱夫特里斯
M·莱利
D·芬克尔斯坦
N·库珀
C·贝利
J·查
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pliant Therapeutics Inc
Original Assignee
Pliant Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliant Therapeutics Inc filed Critical Pliant Therapeutics Inc
Publication of CN112689507A publication Critical patent/CN112689507A/zh
Application granted granted Critical
Publication of CN112689507B publication Critical patent/CN112689507B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
CN201980050125.6A 2018-06-27 2019-06-27 具有无支链接头的氨基酸化合物及其使用方法 Active CN112689507B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862690939P 2018-06-27 2018-06-27
US62/690,939 2018-06-27
PCT/US2019/039624 WO2020006315A1 (en) 2018-06-27 2019-06-27 Amino acid compounds with unbranched linkers and methods of use

Publications (2)

Publication Number Publication Date
CN112689507A CN112689507A (zh) 2021-04-20
CN112689507B true CN112689507B (zh) 2024-07-30

Family

ID=68987528

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980050125.6A Active CN112689507B (zh) 2018-06-27 2019-06-27 具有无支链接头的氨基酸化合物及其使用方法

Country Status (24)

Country Link
US (3) US11396506B2 (https=)
EP (1) EP3813818A4 (https=)
JP (2) JP7425757B2 (https=)
KR (1) KR20210043561A (https=)
CN (1) CN112689507B (https=)
AU (1) AU2019295769B2 (https=)
BR (1) BR112020026278A2 (https=)
CA (1) CA3104682A1 (https=)
CL (1) CL2020003382A1 (https=)
CR (1) CR20210041A (https=)
CU (1) CU24693B1 (https=)
DO (1) DOP2020000255A (https=)
EA (1) EA202190134A1 (https=)
EC (1) ECSP21005655A (https=)
IL (2) IL308960A (https=)
JO (1) JOP20200330A1 (https=)
MX (1) MX2020014086A (https=)
PE (1) PE20210137A1 (https=)
PH (1) PH12020552260A1 (https=)
SA (1) SA520420897B1 (https=)
SG (1) SG11202013027RA (https=)
TW (1) TWI841573B (https=)
WO (1) WO2020006315A1 (https=)
ZA (1) ZA202100211B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3509590A4 (en) 2016-09-07 2020-12-02 Pliant Therapeutics, Inc. N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
US11306084B2 (en) 2016-12-29 2022-04-19 Saint Louis University Integrin antagonists
MA52117A (fr) 2017-02-28 2022-04-06 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
MX394210B (es) 2017-02-28 2025-03-04 Morphic Therapeutic Inc INHIBIDORES DE INTEGRINA AVß6.
FI3761980T3 (fi) 2018-03-07 2024-02-21 Pliant Therapeutics Inc Aminohappoyhdisteitä ja käyttömenetelmiä
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
KR102767739B1 (ko) 2018-06-27 2025-02-12 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물
TWI776067B (zh) 2018-06-29 2022-09-01 美商維托平面玻璃有限責任公司 可燒除保護性塗層
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
SI3844162T1 (sl) 2018-08-29 2025-06-30 Morphic Therapeutic, Inc. Zaviralci integrina alfa v beta6
WO2020047239A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
CN114173803A (zh) 2019-04-08 2022-03-11 普利安特治疗公司 氨基酸化合物的剂型和方案
TW202135812A (zh) * 2019-12-20 2021-10-01 瑞士商諾華公司 使用整聯蛋白抑制劑組合治療肝臟疾病
US20230060422A1 (en) * 2019-12-20 2023-03-02 Novartis Ag Combination treatment of liver diseases using integrin inhibitors
GB202010626D0 (en) * 2020-07-10 2020-08-26 Univ Nottingham Compound
EP4247472A4 (en) 2020-11-19 2024-10-09 Pliant Therapeutics, Inc. INTEGRIN INHIBITORS AND USES THEREOF
GB202209228D0 (en) 2022-06-23 2022-08-10 Univ Strathclyde Modified amino acids and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1284944A (zh) * 1997-12-17 2001-02-21 麦克公司 整联蛋白受体拮抗剂
WO2008093064A1 (en) * 2007-01-29 2008-08-07 Astrazeneca Ab L-ALANINE DERIVATIVES AS α5 BETA 1 ANTAGONISTS
WO2018049068A1 (en) * 2016-09-07 2018-03-15 Pliant Therapeutics, Inc. N-acyl amino acid compounds and methods of use
WO2018119087A1 (en) * 2016-12-23 2018-06-28 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
WO2018160522A1 (en) * 2017-02-28 2018-09-07 Lazuli, Inc. Inhibitors of (alpha-v)(beta-6) integrin

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048861A (en) 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
US6329372B1 (en) * 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
JP2009539815A (ja) * 2006-06-09 2009-11-19 アストラゼネカ アクチボラグ 固形腫瘍の治療用のａ５ｂ１アンタゴニストとしてのＮ−（ベンゾイル）−Ｏ−［２−（ピリジン−２−イルアミノ）エチル］−Ｌ−チロシン誘導体と関連化合物
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
WO2015048819A1 (en) 2013-09-30 2015-04-02 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
WO2016145258A1 (en) 2015-03-10 2016-09-15 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
CN104817604B (zh) 2015-03-16 2017-08-04 邦泰生物工程(深圳)有限公司 一种β‑烟酰胺单核苷酸的纯化方法
BR112017023432A2 (pt) * 2015-04-30 2018-07-24 Scifluor Life Sciences Inc Derivados de ácido propiônico tetra- hidronaftiridinila e usos do mesmo
US11192889B2 (en) 2016-07-05 2021-12-07 The Rockefeller University Tetrahydronaphthyridinepentanamide integrin antagonists
ES2984394T3 (es) * 2016-11-08 2024-10-29 Bristol Myers Squibb Co Compuestos mono y espirocíclicos que contienen ciclobutano y azetidina como inhibidores de la integrina alfa v
MX394210B (es) 2017-02-28 2025-03-04 Morphic Therapeutic Inc INHIBIDORES DE INTEGRINA AVß6.
FI3761980T3 (fi) 2018-03-07 2024-02-21 Pliant Therapeutics Inc Aminohappoyhdisteitä ja käyttömenetelmiä
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
WO2020047239A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN
WO2020047207A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutics, Inc. Inhibitors of (alpha-v)(beta-6) integrin
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
CN114173803A (zh) 2019-04-08 2022-03-11 普利安特治疗公司 氨基酸化合物的剂型和方案
WO2021097338A1 (en) 2019-11-15 2021-05-20 Pliant Therapeutics, Inc. Compositions and methods for activation of integrins
CN115989235A (zh) 2020-05-07 2023-04-18 普利安特治疗公司 使用氨基酸化合物治疗呼吸系统疾病的方法
EP4247472A4 (en) 2020-11-19 2024-10-09 Pliant Therapeutics, Inc. INTEGRIN INHIBITORS AND USES THEREOF
MX2023012794A (es) 2021-04-30 2023-12-15 Pliant Therapeutics Inc Regímenes de dosificación expandidos para inhibidores de integrina.
US20240350494A1 (en) 2021-09-03 2024-10-24 Pliant Therapeutics, Inc. Therapeutic modulation of integrins
TW202329973A (zh) 2021-10-14 2023-08-01 美商普萊恩醫療公司 整合素抑制劑及其與其他藥劑併用之用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1284944A (zh) * 1997-12-17 2001-02-21 麦克公司 整联蛋白受体拮抗剂
WO2008093064A1 (en) * 2007-01-29 2008-08-07 Astrazeneca Ab L-ALANINE DERIVATIVES AS α5 BETA 1 ANTAGONISTS
WO2018049068A1 (en) * 2016-09-07 2018-03-15 Pliant Therapeutics, Inc. N-acyl amino acid compounds and methods of use
WO2018119087A1 (en) * 2016-12-23 2018-06-28 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
WO2018160522A1 (en) * 2017-02-28 2018-09-07 Lazuli, Inc. Inhibitors of (alpha-v)(beta-6) integrin

Also Published As

Publication number Publication date
US20200123151A1 (en) 2020-04-23
PH12020552260A1 (en) 2021-08-16
ZA202100211B (en) 2025-05-28
PE20210137A1 (es) 2021-01-21
JP7425757B2 (ja) 2024-01-31
WO2020006315A1 (en) 2020-01-02
IL279717B2 (en) 2024-05-01
IL308960A (en) 2024-01-01
CU20210001A7 (es) 2021-08-06
US20220289743A1 (en) 2022-09-15
JOP20200330A1 (ar) 2020-12-20
DOP2020000255A (es) 2021-05-16
CA3104682A1 (en) 2020-01-02
AU2019295769A1 (en) 2021-02-11
ECSP21005655A (es) 2021-02-26
CR20210041A (es) 2021-03-02
IL279717B1 (en) 2024-01-01
SG11202013027RA (en) 2021-01-28
MX2020014086A (es) 2021-04-13
TW202010492A (zh) 2020-03-16
EP3813818A4 (en) 2023-01-11
CL2020003382A1 (es) 2021-05-14
BR112020026278A2 (pt) 2021-04-06
JP2021529755A (ja) 2021-11-04
SA520420897B1 (ar) 2024-03-30
KR20210043561A (ko) 2021-04-21
CN112689507A (zh) 2021-04-20
EP3813818A1 (en) 2021-05-05
JP2024055873A (ja) 2024-04-18
TWI841573B (zh) 2024-05-11
EA202190134A1 (ru) 2021-03-26
IL279717A (en) 2021-03-01
AU2019295769B2 (en) 2024-05-23
US11858931B2 (en) 2024-01-02
US20240294520A1 (en) 2024-09-05
CU24693B1 (es) 2024-02-07
US11396506B2 (en) 2022-07-26

Similar Documents

Publication Publication Date Title
CN112689507B (zh) 具有无支链接头的氨基酸化合物及其使用方法
US11952376B2 (en) Substituted amino acids as integrin inhibitors
JP7379467B2 (ja) Ｒｉｐ１阻害剤化合物並びにそれを製造及び使用するための方法
JP2024009916A (ja) Ｒｉｐ１阻害剤化合物並びにそれを製造及び使用するための方法
JP7834830B2 (ja) アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用
EA033626B1 (ru) АМИНОЗАМЕЩЕННЫЕ ИМИДАЗО[1,2-а]ПИРИДИНКАРБОКСАМИДЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ, ИХ ПРИМЕНЕНИЕ И ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ ИХ
JP6749422B2 (ja) プロテインキナーゼ阻害剤である新規な２，３，５−置換チオフェン化合物
EP3197882A1 (en) Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof
TW202329973A (zh) 整合素抑制劑及其與其他藥劑併用之用途
CA3154136C (en) MLL-1 INHIBITORS AND ANTICANCER AGENTS
HK40049583A (en) Amino acid compounds with unbranched linkers and methods of use
BR122023025996A2 (pt) Compostos de aminoácidos, composição farmacêutica e kit compreendendo os mesmos, seus usos, e seu método de produção
WO2026047577A1 (en) Hydroquinazoline derivatives and treatment of a disease or disorder using the same
EA050655B1 (ru) Замещенные бициклические соединения, пригодные для применения в качестве ингибиторов tlr9
EA045845B1 (ru) Противовирусные средства для лечения и профилактики вич-инфекции

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40049583

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant